Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Cancer research award to UConn resident

Dr. Joshua A. Fein, a third-year resident in the UConn internal medicine residency program and current applicant for hematology/oncology fellowship programs, has been selected by...

| By Kelley Gipson

Undergrads at UConn get research experience

The Undergraduate Research Program at UConn offers students interested in health and biomedical sciences a unique first-hand experience to work at UConn Health. In a...

| By Kelley Gipson

FDA approves Cara’s KORSUVA™ for dialysis patients

Cara Therapeutics and Vifor Pharma report that the FDA has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...

| By Kelley Gipson

FDA approves Pfizer-BioNTech COVID-19 Vaccine

The FDA has approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee),...

| By Kelley Gipson

UConn studies treating asthma with nanocapsules

A team of UConn researchers –- including Assistant Professor of Chemistry in the College of Liberal Arts and Sciences Jessica Rouge and Associate Professor of...

| By Kelley Gipson

Sema4, Avera to collaborate on precision care

Avera Health and Sema4 have launched a new precision medicine initiative. Avera Cancer Institute has had a robust precision oncology program for several years in...

| By Kelley Gipson

Japan patent allowance re Bioasis fusion proteins

Bioasis Technologies reports that the Japanese Patent Office has issued Japanese Patent No. 2019-189551 Notice of Allowance for the company’s xB3-IDS fusion proteins. “We are excited...